Jaguar Health JV Initiates Preclinical Study of Coca Extract for Post-GLP-1 Weight Loss
Summary
Magdalena Biosciences, a joint venture between Jaguar Health (JAGX) and Filament Health (FLHLF), has initiated a preclinical study evaluating a whole leaf coca extract for appetite suppression, specifically targeting post-GLP-1 weight loss management. For Jaguar Health, this represents a concrete step forward in advancing a novel drug candidate into its development pipeline. This news also impacts Filament Health, which recently announced a definitive agreement to be acquired by Red Light Holland Corp. on March 10th, making this an asset development for the acquiring entity. While preclinical, this initiation demonstrates progress in a potentially large market, and traders will monitor future updates on the study's results and any progression to clinical trials.
At the time of this announcement, JAGX was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.46 to $15.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Acceswire.